183 related articles for article (PubMed ID: 35348812)
1. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Her JH; Pretscher D; Patra-Kneuer M; Schanzer J; Cho SY; Hwang YK; Hoeres T; Boxhammer R; Heitmueller C; Wilhelm M; Steidl S; Endell J
Cancer Immunol Immunother; 2022 Nov; 71(11):2829-2836. PubMed ID: 35348812
[TBL] [Abstract][Full Text] [Related]
2. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Salles G; Długosz-Danecka M; Ghesquières H; Jurczak W
Expert Opin Biol Ther; 2021 Apr; 21(4):455-463. PubMed ID: 33554668
[TBL] [Abstract][Full Text] [Related]
3. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
Lu Q; Huang H; Tang S; Wang Y; Yang DH
Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
[TBL] [Abstract][Full Text] [Related]
4. Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M; Chang G; Xu W; Augsberger C; Grau M; Zapukhlyak M; Ilieva K; Landgraf K; Mangelberger-Eberl D; Yousefi K; Berning P; Kurz KS; Ott G; Klener P; Khandanpour C; Horna P; Schanzer J; Steidl S; Endell J; Heitmüller C; Lenz G
Front Immunol; 2023; 14():1220558. PubMed ID: 37600821
[TBL] [Abstract][Full Text] [Related]
5. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
6. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
7. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma.
Yoon DH; Koh Y; Jung M; Kwak JE; Shin EC; Hwang YK; Kim WS
Transplant Cell Ther; 2023 Apr; 29(4):253.e1-253.e9. PubMed ID: 36610490
[TBL] [Abstract][Full Text] [Related]
9. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
[TBL] [Abstract][Full Text] [Related]
10. Tafasitamab: First Approval.
Hoy SM
Drugs; 2020 Nov; 80(16):1731-1737. PubMed ID: 32946059
[TBL] [Abstract][Full Text] [Related]
11. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell J; Maddocks KJ; González-Barca E; Jurczak W; Liberati AM; De Vos S; Nagy Z; Obr A; Gaidano G; Abrisqueta P; Kalakonda N; André M; Dreyling M; Menne T; Tournilhac O; Augustin M; Rosenwald A; Dirnberger-Hertweck M; Weirather J; Ambarkhane S; Salles G
Haematologica; 2021 Sep; 106(9):2417-2426. PubMed ID: 34196165
[TBL] [Abstract][Full Text] [Related]
13. The use of tafasitamab in diffuse large B-cell lymphoma.
Düll J; Topp M; Salles G
Ther Adv Hematol; 2021; 12():20406207211027458. PubMed ID: 34285786
[TBL] [Abstract][Full Text] [Related]
14. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Pirosa MC; Stathis A; Zucca E
Hum Vaccin Immunother; 2024 Dec; 20(1):2309701. PubMed ID: 38299612
[TBL] [Abstract][Full Text] [Related]
15. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
16. RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Zinzani PL; Rodgers T; Marino D; Frezzato M; Barbui AM; Castellino C; Meli E; Fowler NH; Salles G; Feinberg B; Kurukulasuriya NC; Tillmanns S; Parche S; Dey D; Fingerle-Rowson G; Ambarkhane S; Winderlich M; Nowakowski GS
Clin Cancer Res; 2021 Nov; 27(22):6124-6134. PubMed ID: 34433649
[TBL] [Abstract][Full Text] [Related]
17. Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Nedved A; Maddocks K; Nowakowski GS
Oncologist; 2023 Mar; 28(3):199-207. PubMed ID: 36648324
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis.
Moore DC; Eagers KA; Janes A; Pineda-Roman M
J Oncol Pharm Pract; 2023 Jan; 29(1):239-241. PubMed ID: 35585701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]